How has been the historical performance of Indo US Bio-Tech?

Answer:The historical performance of Indo US Bio-Tech shows a steady growth in net sales and profitability over the past three years.

Breakdown:
Indo US Bio-Tech's net sales increased from 39.76 Cr in March 2020 to 50.06 Cr in March 2022, reflecting a positive trend in revenue generation. The total operating income followed the same pattern, rising from 39.76 Cr in March 2020 to 50.06 Cr in March 2022. However, the raw material cost surged significantly from 3.59 Cr in March 2020 to 45.20 Cr in March 2022, impacting the overall expenditure, which also increased from 35.78 Cr to 43.29 Cr during the same period. Despite these rising costs, the operating profit (PBDIT) improved from 3.99 Cr in March 2020 to 6.95 Cr in March 2022, indicating better operational efficiency. Profit before tax also rose from 2.86 Cr to 5.31 Cr, while profit after tax saw a slight increase from 2.53 Cr to 5.06 Cr. The company's total assets grew from 34.70 Cr in March 2020 to 55.20 Cr in March 2022, with total liabilities also increasing from 34.70 Cr to 55.20 Cr. The cash flow from operating activities turned positive in March 2022 at 2.00 Cr, compared to zero in the previous years, indicating improved cash generation capabilities. Overall, Indo US Bio-Tech has demonstrated a solid growth trajectory in sales and profitability, alongside an increase in assets and liabilities.